Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus‐coinfected patients with compensated liver cirrhosis

Nicolás Merchante, Antonio Rivero‐Juárez, Francisco Téllez, Dolores Merino, Maria José Ríos‐Villegas, Manuel Márquez‐Solero, Mohamed Omar, Juan Macías, Ángela Camacho, Montserrat Pérez‐Pérez, Jesús Gómez‐Mateos, Antonio Rivero, Juan Antonio Pineda, on behalf of the Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI) – 25 January 2012 – Our aim was to assess the predictive value of liver stiffness (LS), measured by transient elastography (TE), for clinical outcome in human immunodeficiency virus / hepatitis C virus (HIV/

Early transcriptional programming links progression to hepatitis C virus–induced severe liver disease in transplant patients

Angela L. Rasmussen, Nicolas Tchitchek, Nathan J. Susnow, Alexei L. Krasnoselsky, Deborah L. Diamond, Matthew M. Yeh, Sean C. Proll, Marcus J. Korth, Kathie‐Anne Walters, Sharon Lederer, Anne M. Larson, Robert L. Carithers, Arndt Benecke, Michael G. Katze – 25 January 2012 – Liver failure resulting from chronic hepatitis C virus (HCV) infection is a major cause for liver transplantation worldwide. Recurrent infection of the graft is universal in HCV patients after transplant and results in a rapid progression to severe fibrosis and end‐stage liver disease in one third of all patients.

Performance of magnetic resonance elastography and diffusion‐weighted imaging for the staging of hepatic fibrosis: A meta‐analysis

Qing‐Bing Wang, Hui Zhu, Hai‐Ling Liu, Bei Zhang – 25 January 2012 – A meta‐analysis was performed to assess and compare the accuracies of magnetic resonance elastography (MRE) and diffusion‐weighted imaging (DWI) for the staging of hepatic fibrosis. Online journal databases and a manual search from January 2000 to May 2011 were used. We identified 41 studies, but only 14 met the criteria to perform a meta‐analysis assessing MRE (five trials) or DWI (10 trials). Fibrosis was categorized by redistribution into five stages according to histopathological description.

Inhibitory effects of microRNA 19b in hepatic stellate cell‐mediated fibrogenesis

Ashley M. Lakner, Nury M. Steuerwald, Tracy L. Walling, Sriparna Ghosh, Ting Li, Iain H. McKillop, Mark W. Russo, Herbert L. Bonkovsky, Laura W. Schrum – 25 January 2012 – Hepatic stellate cell (HSC) activation is a pivotal event in initiation and progression of hepatic fibrosis and a major contributor to collagen deposition driven by transforming growth factor beta (TGF‐β). MicroRNAs (miRs), small noncoding RNAs modulating messenger RNA (mRNA) and protein expression, have emerged as key regulatory molecules in chronic liver disease.

Cidea promotes hepatic steatosis by sensing dietary fatty acids

Linkang Zhou, Li Xu, Jing Ye, De Li, Wenshan Wang, Xuanhe Li, Lizhen Wu, Hui Wang, Feifei Guan, Peng Li – 25 January 2012 – High levels of dietary saturated fat have been closely associated with the development of hepatic steatosis, but the factors that mediate this process remain elusive. Here, we observed that the level of cell death‐inducing DNA fragmentation factor‐alpha‐like effector a (Cidea) expression was highly correlated with the severity of hepatic steatosis in humans.

Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels

Teresa Pollicino, Giuliana Amaddeo, Agnese Restuccia, Giuseppina Raffa, Angela Alibrandi, Giuseppina Cutroneo, Angelo Favaloro, Sergio Maimone, Giovanni Squadrito, Giovanni Raimondo – 23 January 2012 – To evaluate whether hepatitis B virus (HBV) preS/S gene variability has any impact on serum hepatitis B surface antigen (HBsAg) levels and to analyze the replication capacity of naturally occurring preS/S variants, sera from 40 untreated patients with HBV‐related chronic liver disease (hepatitis B e antigen [HBeAg]‐positive, n = 11; HBeAg‐negative, n = 29) were virologically characterized.

Cyclin G1–mediated epithelial‐mesenchymal transition via phosphoinositide 3‐kinase/Akt signaling facilitates liver cancer progression

Wen Wen, Jin Ding, Wen Sun, Jing Fu, Yao Chen, Kun Wu, Beifang Ning, Tao Han, Lei Huang, Cheng Chen, Dong Xie, Zhong Li, Gensheng Feng, Mengchao Wu, Weifen Xie, Hongyang Wang – 23 January 2012 – Cyclin G1 deficiency is associated with reduced incidence of carcinogen‐induced hepatocellular carcinoma (HCC), but its function in HCC progression remains obscure. We report a critical role of cyclin G1 in HCC metastasis. Elevated expression of cyclin G1 was detected in HCCs (60.6%), and its expression levels were even higher in portal vein tumor thrombus.

A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list

Christian Toso, Elise Dupuis‐Lozeron, Pietro Majno, Thierry Berney, Norman M. Kneteman, Thomas Perneger, Philippe Morel, Gilles Mentha, Christophe Combescure – 23 January 2012 – In many countries, the allocation of liver grafts is based on the Model of End‐stage Liver Disease (MELD) score and the use of exception points for patients with hepatocellular carcinoma (HCC). With this strategy, HCC patients have easier access to transplantation than non‐HCC ones.

Pulmonary function in individuals who underwent liver transplantation: From the US cystic fibrosis foundation registry

Melissa R. Miller, Ronald J. Sokol, Michael R. Narkewicz, Marci K. Sontag – 23 January 2012 – Severe liver disease affects 4.5% to 10% of individuals with cystic fibrosis (CF) and is the third‐leading cause of death. Liver transplantation (LT) is an accepted therapy, but the effects of liver disease and LT on pulmonary function in patients with CF are controversial. Our aim was to characterize changes in pulmonary function in LT patients with CF.

Noninvasive elastography‐based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis

Christophe Corpechot, Fabrice Carrat, Armelle Poujol‐Robert, Farid Gaouar, Dominique Wendum, Olivier Chazouillères, Raoul Poupon – 23 January 2012 – The development of liver fibrosis markers in primary biliary cirrhosis (PBC) is needed to facilitate the assessment of its progression and the effectiveness of new therapies. Here, we investigated the potential usefulness of transient elastography (TE) in the noninvasive evaluation of liver fibrosis stage and disease progression in PBC.

Subscribe to